Dr. Miron on first-line treatment selection in bladder cancer

Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.

Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a real-world study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on overall survival outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.